WHEN: Today, Monday, June 1st
WHERE: CNBC's Business Day Programming
Following are excerpts from the unofficial transcripts of CNBC EXCLUSIVE interviews with AstraZeneca Executive Director & CEO Pascal Soriot and Pfizer Chairman & CEO Ian Read throughout CNBC's Business Day programming live from the ASCO conference today. Video from the interviews are available on CNBC.com.
All references must be sourced to CNBC.
Pascal Soriot, AstraZeneca Executive Director & CEO
SORIOT ON CANCER DRUGS
We are at the very beginning of, I think, a long journey developing combinations of products that will really turn the immune system against the cancer. So it's really so exciting we're going to see the treatment of cancer completely transformed over the next five to ten years.
SORIOT ON COMBINATION THERAPY
We're even moving to combination now in Melanoma. The same is happening in lung cancer and we actually took the bet more than two years ago that combination was going to be the way to go and now we are looking like we could be the frontrunner in lung cancer treatment with combination regiments.
SORIOT ON CANCER TREATMENTS
It looks like different treatments may be needed depending on the cancer types. And so, you know, there's a lot of work that is happening today to better understand that. And as I said, we are at the beginning of a journey and this journey will end up with a series of combinations of products that will all probably be different depending on whether you go after lung cancer or colorectal cancer.
Ian Read, Pfizer Chairman & CEO
READ ON IBRANCE
As to grasp the product, we launched in the first quarter and since then we have taken our market share from 10 to 20% in the first line. We've doubled the number of patients, doubled the number of physicians that are prescribing, so the launch is going well which means it's been well received by physicians.
READ ON DRUG COST
I think you have to look at drug pricing – number one, it's a sensitive issue, it's an emotional issue, especially for patients; so we believe that the way to deal with this is that patients should have good quality insurance with low copays. And when they don't have good insurance or they have no insurance, Pfizer and most of the industry stands ready to provide our drugs at no cost or very little cost.
With CNBC in the U.S., CNBC in Asia Pacific, CNBC in Europe, Middle East and Africa, CNBC World and CNBC HD , CNBC is the recognized world leader in business news and provides real-time financial market coverage and business information to approximately 371 million homes worldwide, including more than 100 million households in the United States and Canada. CNBC also provides daily business updates to 400 million households across China. The network's 15 live hours a day of business programming in North America (weekdays from 4:00 a.m. - 7:00 p.m. ET) is produced at CNBC's global headquarters in Englewood Cliffs, N.J., and includes reports from CNBC News bureaus worldwide. CNBC at night features a mix of new reality programming, CNBC's highly successful series produced exclusively for CNBC and a number of distinctive in-house documentaries.
CNBC also has a vast portfolio of digital products which deliver real-time financial market news and information across a variety of platforms. These include CNBC.com, the online destination for global business; CNBC PRO, the premium, integrated desktop/mobile service that provides real-time global market data and live access to CNBC global programming; and a suite of CNBC Mobile products including the CNBC Real-Time iPhone and iPad Apps.
Members of the media can receive more information about CNBC and its programming on the NBC Universal Media Village Web site at http://www.nbcumv.com/mediavillage/networks/cnbc/.